About the conference

China’s biologics market continues to aggressively expand and achieve greater heights – regulatory reforms, new investments into the biopharma sector, more international partnerships coming into place and local biopharmas looking to go global. Product innovation and investment opportunities are in abundance as China leads the way as the 2nd largest biologics market in the world.

With numerous shifts on the horizon, the Chinese industry approaches a tipping point as companies reevaluate current trends and strategies to achieve commercial excellence. The 6th iteration of BDP Week will address the 2020 investment climate, technological advancements, industry case studies, and partnerships and expansion opportunities across key value chains.

With improved networking windows and elevated exhibition platforms, join us as the industry convenes at this highly anticipated annual gathering of biopharma leaders.

AGENDA AT-A-GLANCE

Conference Day 1 | 19 May 2020

Plenary

Keynote Address:
China’s Pharma Innovation and Technology: BioPharma 2020 and the Next Big Thing

Manufacturers’ Panel:
Expansion, Business Models, Investment and Technology – Addressing Manufacturing Insights

  • Changing manufacturing business models and how do Chinese manufacturers are sufficiently deploying strengths
  • Going even more global – Capacity, opportunity, and partnerships
  • What is the size of the gap on quality, investment, rapid expansion?
  • Generic Quality Consistency Evaluation (GQCE) – quality consistency and better pricing
  • Biomanufacturing 4.0 – Where are we at?
  • New therapeutics manufacturing, commercialisation and global access
  • DAL’s GAMP and licencing laws – How is it affecting our business and what we can expect?
  • DAL’s New GAMP and Licensing Law – Implementation and oversight
  • CDMOs presentations
  • GAMP and Data Integrity requirement – in the case of CDMO, CMO and outsourcing
  • Biomanufacturing 4.0, China’s great leap
  • Digital upgrade case studies on China’s biomanufacturing landscape
  • China’s biological facilities for the future

 

  • Chinese cell line investment market landscape
  • Cell line product quality control strategies
  • Cell culture technology trends in China
  • Automation, digitalisation and integration of big data
  • Genome editing technology showcases for CHO cells
  • Use cases for new host cell lines apart from CHO
  • Genomics: gene editing / CRISPR, cellular engineering case studies

 

  • China: Biosimilars powerhouse – What’s next?
  • Regulatory reviews benchmarks – CFDA, EMA and US FDA
  • Therapeutics based pipeline outlook
  • Technology showcases
  • Innovation and differentiation of products
  • Investment, finance and going public

 

Networking Cocktails & BDP China Party

Conference Day 2 | 20 May 2020

Plenary

Keynote Address:
China’s Biopharma Capital Markets – Future Funds and Innovative Financing

Venture Capitals Panel:
Show Me the Money – VCs’ Perspectives on Booming Chinese Biopharma Market

  • Investment landscape of Chinese biopharma market
  • Mergers, partnership, expansion and JV – Where do we see transactions picking up?
  • Financing new manufacturing plant, new therapeutics, product launch and scaling-up operations – How do we review?
  • Manufacturing 4.0 – How do VCs and banks play a part in modernising the value chain?
  • Win – win models in spotlight

  • Meeting changing product portfolios and meeting demand – single-use, continuous and small batch manufacturing
  • Manufacturing technology showcases – Improving cost and efficiency
  • QbD and Quality Matrix for meeting regulatory requirements
  • PAT insights – Assessment, Review and Results
  • Cell and gene therapy manufacturing
  • Sustainable manufacturing and scalability

 

  • Future of antibody discovery and cell line development
  • Engineering targets for antibody production
  • Streamlining CLD process
  • Data science and accelerating product cycle
  • Partnerships, M&A in focus – Local and Global
  • East Asian pipeline showcases
  • Global biosimilar retails market and international access case studies
  • Pricing of biosimilars – Perspectives from New Medical Reimbursement agency
  • Addressing access constraints and reimbursement negotiations
  • Product innovations

 

End of Conference